The tesamorelin dosage protocol is uniquely grounded in FDA-validated Phase III clinical trial data — because tesamorelin (brand name Egrifta) is the only growth hormone releasing hormone (GHRH) peptide ever approved by the FDA, and the only GHRH analog with a regulatory-validated dosing schedule. The standard tesamorelin dosage of 2mg subcutaneous daily was established through two Phase III randomized controlled trials (pooled analysis: 806 participants, Falutz et al.) that demonstrated approximately 15.4% reduction in visceral adipose tissue versus placebo at 26 weeks (p<0.001). No other GH peptide — not Sermorelin, not CJC-1295, not Ipamorelin — has this level of dosing validation.

Tesamorelin at PSPeptides is available from $59.99 at 99%+ HPLC-verified purity with batch-specific COAs. The free PSPeptides calculator supports tesamorelin dosage preparation at any concentration with visual syringe output.

Tesamorelin Dosage: The FDA-Validated Protocol

Tesamorelin Dosage: Reconstitution and Syringe Math

The 10mg vial ($89.99) provides better per-milligram value: $8.99/mg versus $11.99/mg for the 5mg. For the standard tesamorelin dosage of 2mg daily, one 10mg vial provides 5 days of research. A 26-week protocol (the Phase III duration) requires approximately 37 vials of 5mg or 19 vials of 10mg — the free PSPeptides calculator handles the exact math at any reconstitution volume. The reconstitution guide covers preparation. bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads ship in the same checkout.

Tesamorelin Dosage: How It Compares to Other GH Peptides

The tesamorelin dosage advantage over other GH peptides: FDA approval means the most comprehensive safety and efficacy characterization available for any GHRH peptide. The Phase III validation with 806 participants provides the highest-confidence dosing data in the entire GH secretagogue class. The CJC/Ipamorelin guide covers the synergistic alternative. The stacking guide covers combination protocols.

Tesamorelin Dosage: The GLP-1 Muscle Preservation Stack

One of the most important applications for the tesamorelin dosage protocol in 2026: stacking with GLP-1 compounds to preserve lean mass during weight loss. Published data shows up to 40% of weight lost on semaglutide is lean mass. The tesamorelin dosage (2mg daily) produces physiological GH/IGF-1 elevation that promotes muscle protein synthesis and opposes the catabolism that caloric deficit creates. Order Tesamorelin at PSPeptides alongside retatrutide from $39.99 or tirzepatide from $54.99 in one checkout for the complete body composition research protocol. The GLP-1 muscle preservation guide covers this protocol in detail.

Tesamorelin at PSPeptides from $59.99. The only FDA-approved GHRH peptide. bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads in the same checkout. PubMed indexes tesamorelin clinical data. Wikipedia covers tesamorelin pharmacology. The half-life chart covers GH peptide timing.

Tesamorelin Mechanism of Action: How the GHRH Pathway Works

Understanding the tesamorelin dosage requires a foundational grasp of how this peptide operates at the receptor level. Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), a 44-amino acid hypothalamic peptide. Unlike native GHRH, this compound has a trans-3-hexenoic acid group added to its N-terminus, which significantly improves metabolic stability by protecting against dipeptidyl peptidase IV (DPP-IV) degradation. This structural modification extends the functional half-life while preserving full agonist activity at the GHRH receptor (GHRHR).

When the 2mg dose is administered subcutaneously, the peptide binds to GHRHR on pituitary somatotroph cells. This receptor coupling activates the adenylyl cyclase/cAMP signaling cascade, leading to protein kinase A (PKA) activation and subsequent phosphorylation of transcription factors that drive GH synthesis and secretion. Critically, this compound maintains the pulsatile pattern of GH release — it amplifies natural GH pulses rather than producing supraphysiological continuous GH elevation. Published data from the Phase III trials shows mean GH peak values rose from approximately 3.2 ng/mL at baseline to 7.1 ng/mL following the standard protocol, a pattern consistent with preserved hypothalamic-pituitary-adrenal (HPA) axis feedback regulation.

The downstream cascade from GH secretion involves IGF-1 production primarily in the liver, which mediates many of tesamorelin’s metabolic effects. In the Falutz 2010 trial, IGF-1 levels increased by a mean of approximately 81 ng/mL (about 19% above baseline) in the treatment group versus minimal change in placebo subjects. This IGF-1 elevation drives adipocyte lipolysis in visceral adipose tissue through hormone-sensitive lipase activation, explaining the specific reduction in visceral — but not subcutaneous — fat observed in clinical studies. Researchers studying this compound note that the visceral-specific fat reduction appears linked to the differential density of GH receptors in visceral versus subcutaneous adipocytes.

Published Research Supporting the Standard Tesamorelin Dosage

The evidence base for the 2mg daily protocol is substantially deeper than most GHRH peptides. Three pivotal studies form the core evidence and are worth understanding in detail for any serious researcher reviewing this compound.

The Falutz et al. (2007) Phase III randomized controlled trial enrolled 412 HIV-infected adults with abdominal fat accumulation. Participants received either the standard tesamorelin dosage of 2mg subcutaneous daily or placebo for 26 weeks. The primary endpoint — change in visceral adipose tissue (VAT) by CT scan — showed a mean reduction of 15.2% in the active group versus a 5.0% increase in placebo (p<0.0001). Secondary endpoints included trunk fat (dual-energy X-ray absorptiometry), which showed significant reduction (−0.65 kg vs +0.23 kg), and IGF-1 elevation confirming target engagement. Fasting glucose and HbA1c remained stable in both groups, addressing early safety concerns about GH-axis stimulation and diabetes risk.

The Falutz et al. (2010) confirmatory Phase III trial enrolled 404 participants using the same protocol. This trial added an important extension: at week 26, half of the active group was re-randomized to placebo to assess durability. Participants who continued the standard dosing maintained VAT reduction at week 52 (−15.4% from baseline), while those switched to placebo experienced VAT rebound toward baseline values within 26 weeks — confirming that continuous daily administration is required to sustain effects. This finding directly informed the FDA-approved prescribing guidance.

A third relevant analysis — the Snyder et al. (2012) pooled analysis of both Phase III trials — examined metabolic safety across 806 participants. Rates of glucose elevation, new-onset diabetes, and IGF-1 supraphysiological elevation were assessed. The tesamorelin dosage of 2mg daily did not produce a statistically significant increase in diabetes incidence versus placebo over 26 weeks, though IGF-1 elevations above the upper limit of normal occurred in approximately 34% of participants. Researchers reviewing this data note that IGF-1 monitoring is a standard consideration in any GH secretagogue protocol.

Tesamorelin Dosage Timing and Circadian Optimization

The FDA-approved protocol specifies once-daily subcutaneous administration without a mandated time of day, but research into GH physiology provides important context for timing decisions. Endogenous GH secretion follows a circadian pattern with the largest pulse occurring approximately 1 hour after sleep onset, coinciding with slow-wave sleep. Some researchers prefer evening administration of the 2mg dose to align peptide activity with this natural peak window, potentially producing a synergistic amplitude effect on the nocturnal GH pulse.

The Phase III trials administered this compound at a consistent daily time without specifying morning or evening, meaning the 15.4% VAT reduction endpoint was achieved regardless of timing. The most consistent recommendation emerging from the research literature is that the key variable is consistency — administering the tesamorelin dosage at the same time each day. Because this peptide stimulates GH secretion within 30-60 minutes of injection (based on pharmacokinetic data showing peak plasma concentrations at approximately 0.5 hours post-injection), researchers studying circadian optimization typically choose either morning fasting or pre-sleep administration and maintain that timing throughout the protocol. The half-life of tesamorelin itself is approximately 26 minutes, placing it firmly in the short-acting GHRH analog category.

For protocols examining this peptide in combination with GLP-1 receptor agonists or other compounds, timing coordination becomes more nuanced. Research protocols examining it alongside compounds affecting appetite, insulin sensitivity, or GH pulsatility should account for potential interactions at the receptor-level timing window. The peptide stacking guide provides broader context for multi-compound protocol design. Researchers should also review the peptide cycling guide for protocol duration and rest period considerations applicable to extended GH secretagogue research.

Safety Profile and Adverse Events at the Standard Tesamorelin Dosage

The 2mg daily protocol has the most thoroughly characterized safety profile of any GHRH peptide, owing entirely to its FDA approval pathway. The pooled Phase III safety data from 806 participants provides adverse event rates that researchers can reference with high confidence — a level of characterization unavailable for any non-approved GH secretagogue.

Injection-site reactions were the most commonly reported adverse events, occurring in approximately 8.5% of the active group versus 2.6% in placebo subjects. These were predominantly mild-to-moderate erythema, pruritus, or localized edema, and rarely led to study discontinuation. Fluid retention-related effects — edema, arthralgia, myalgia — occurred in about 6-10% of subjects, consistent with the GH-axis mechanism and comparable to rates seen with exogenous GH therapy. Importantly, these effects were generally reversible upon cessation of the tesamorelin dosage.

Glucose metabolism effects require careful monitoring consideration. IGF-1 supraphysiological elevation (above the age-adjusted upper limit of normal) occurred in approximately 34% of participants receiving the standard protocol versus 5% in placebo. Despite this, new-onset diabetes was not significantly more frequent in the active group over 26 weeks. However, the prescribing information notes that this compound is contraindicated in active malignancy and in individuals with disruption of hypothalamic-pituitary axis integrity. The comprehensive peptide side effects guide covers this topic in broader context across the GH secretagogue class.

Tesamorelin Dosage Considerations for Long-Term Research Protocols

The long-term use data for this protocol extends to 52 weeks from the Phase III extension cohort, making tesamorelin one of the more extensively studied GHRH peptides from a durability perspective. Published data from the Falutz 2010 extension phase showed that continued tesamorelin dosage at 2mg daily maintained the VAT reduction achieved at 26 weeks, with no significant additional adverse events emerging in the extended observation period. This durability profile — consistent efficacy with a stable safety signal — distinguishes this compound from research contexts where tolerance or diminishing response has been observed.

Researchers designing multi-cycle protocols should note the rebound data: participants who discontinued after 26 weeks experienced a return toward baseline VAT within approximately 3-6 months. This suggests that any protocol examining this compound’s effects on visceral fat requires either continuous administration or careful consideration of the washout timeline when comparing pre- and post-intervention measurements. The finding also confirms that tesamorelin’s effects are mediated through ongoing GH-axis stimulation rather than permanent adipose tissue remodeling.

For researchers interested in broader GH secretagogue comparisons, the CJC-1295 Ipamorelin guide covers the most commonly studied non-approved alternative, while the peptide reconstitution guide provides step-by-step preparation protocols applicable to research. Understanding the peptide half-life chart helps contextualize why once-daily tesamorelin dosage achieves sustained effects despite the peptide’s short plasma half-life — it is the downstream IGF-1 elevation that persists, not the peptide itself.

PSPeptides: Verified Quality, Complete Supplies, 24/7 Support

PSPeptides provides 99%+ HPLC-verified peptides with batch-specific COAs from independent laboratories. US manufacturing. Same-day processing seven days a week including Sundays. Free shipping on every domestic order. Free international shipping to 30+ countries over $150. Zero fees on Affirm, Afterpay, Zelle, cards, Apple Pay, Google Pay. Discrete plain white mailer packaging. bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads in one checkout. free PSPeptides calculator with visual syringe diagrams. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670. 5-star from thousands of verified customers at pspeptides.com/shop.

Understanding tesamorelin dosage is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions About Tesamorelin Dosage

What is the standard tesamorelin dosage for research protocols?

The FDA-validated protocol is 2mg administered subcutaneously once daily. This dose was established through two Phase III randomized controlled trials (pooled n=806, Falutz et al. 2007 and 2010) that demonstrated approximately 15.4% visceral adipose tissue reduction versus placebo at 26 weeks (p<0.001). No other GHRH peptide has this level of regulatory-validated dosing data — making the 2mg daily protocol the highest-confidence tesamorelin dosage in the research literature. Consistency of administration timing is recommended, though the trials did not mandate a specific time of day.

Is tesamorelin FDA-approved and what does that mean for research?

Yes. Tesamorelin (brand name Egrifta, later EGRIFTA WR) is the only FDA-approved GHRH peptide analog. Initial approval came in 2010 for HIV-associated lipodystrophy; the updated EGRIFTA WR formulation received FDA approval in March 2025. This regulatory status means the 2mg daily tesamorelin dosage has undergone Phase III safety and efficacy evaluation — providing a level of adverse event characterization, pharmacokinetic data, and dosing validation that non-approved GHRH peptides lack. For research purposes, this documented safety profile is one of the primary reasons researchers select this compound over alternatives like Sermorelin or CJC-1295.

How do I reconstitute tesamorelin for the 2mg daily protocol?

For a standard 5mg vial, add 2mL of bacteriostatic water to achieve a concentration of 2.5mg/mL. At this concentration, the 2mg daily dose requires 0.8mL, which equals 80 units on an insulin syringe. For a 10mg vial reconstituted with 4mL BAC water, the concentration remains 2.5mg/mL and the syringe math is identical. The free PSPeptides peptide calculator provides real-time visual syringe unit calculations at any reconstitution volume. Store reconstituted peptide refrigerated at 2-8°C and use within 30 days; lyophilized (unmixed) vials may be stored at room temperature below 25°C away from direct light.

Does PSPeptides sell tesamorelin for research?

Yes. Tesamorelin at PSPeptides is available from $59.99 with 99%+ HPLC-verified purity and batch-specific Certificates of Analysis (COAs) available for every product. PSPeptides offers free shipping, same-day processing on orders placed before 2pm EST, and flexible payment options including Affirm and Afterpay at zero additional fees. Research supplies — bacteriostatic water, EasyTouch insulin syringes, and alcohol prep pads — are all available in one checkout. Customer support is available 24/7 via live chat, email ([email protected]), and phone/text at (551) 284-2670.

What monitoring considerations apply to the tesamorelin dosage protocol?

Based on Phase III data, IGF-1 monitoring is a key consideration — approximately 34% of participants in the pooled analysis experienced IGF-1 elevation above the age-adjusted upper limit of normal. Glucose and HbA1c monitoring may also be relevant, as GH-axis stimulation can influence insulin sensitivity. The pooled trial data showed no statistically significant increase in new-onset diabetes over 26 weeks at the standard tesamorelin dosage, but individual metabolic response varies. Injection-site monitoring for erythema or edema is standard practice; these reactions were mild-to-moderate in approximately 8.5% of trial participants and typically self-resolving.

All PSPeptides products are sold exclusively for research and laboratory use.